Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Vaidyanathan Ganapathy & Michael D Stensland. (2017) Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1793-1801.
Read now
Read now
Thomas J. Monaco & Nicola A. Hanania. (2017) Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opinion on Emerging Drugs 22:3, pages 285-299.
Read now
Read now
Yaozhu J. Chen, Charles Makin, Vamsi K. Bollu, Maryam Navaie & Bartolome R. Celli. (2016) Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting 2-agonists. Journal of Medical Economics 19:1, pages 11-20.
Read now
Read now
Chee H Loh, James F Donohue & Jill A Ohar. (2015) Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opinion on Drug Safety 14:3, pages 463-472.
Read now
Read now
Rajiv Dhand, Myrna Dolovich, Bradley Chipps, Timothy R. Myers, Ruben Restrepo & Judith Rosen Farrar. (2012) The Role of Nebulized Therapy in the Management of COPD: Evidence and Recommendations. COPD: Journal of Chronic Obstructive Pulmonary Disease 9:1, pages 58-72.
Read now
Read now
Articles from other publishers (15)
S.K. Katiyar, S.N. Gaur, R.N. Solanki, Nikhil Sarangdhar, J.C. Suri, Raj Kumar, G.C. Khilnani, Dhruva Chaudhary, Rupak Singla, Parvaiz A. Koul, Ashok A. Mahashur, A.G. Ghoshal, D. Behera, D.J. Christopher, Deepak Talwar, Dhiman Ganguly, H. Paramesh, K.B. Gupta, Mohan Kumar T, P.D. Motiani, P.S. Shankar, Rajesh Chawla, Randeep Guleria, S.K. Jindal, S.K. Luhadia, V.K. Arora, V.K. Vijayan, Abhishek Faye, Aditya Jindal, Amit K. Murar, Anand Jaiswal, Arunachalam M, A.K. Janmeja, Brijesh Prajapat, C. Ravindran, Debajyoti Bhattacharyya, George D'Souza, Inderpaul Singh Sehgal, J.K. Samaria, Jogesh Sarma, Lalit Singh, M.K. Sen, Mahendra K. Bainara, Mansi Gupta, Nilkanth T. Awad, Narayan Mishra, Naveed N. Shah, Neetu Jain, Prasanta R. Mohapatra, Parul Mrigpuri, Pawan Tiwari, R. Narasimhan, R. Vijai Kumar, Rajendra Prasad, Rajesh Swarnakar, Rakesh K. Chawla, Rohit Kumar, S. Chakrabarti, Sandeep Katiyar, Saurabh Mittal, Sonam Spalgais, Subhadeep Saha, Surya Kant, V.K. Singh, Vijay Hadda, Vikas Kumar, Virendra Singh, Vishal Chopra & Visweswaran B. (2022) Indian Guidelines on Nebulization Therapy. Indian Journal of Tuberculosis 69, pages S1-S191.
Crossref
Crossref
Fabiola E Tristán-Flores, Diana Casique-Aguirre, Raquel Pliego-Arreaga, Juan A Cervantes-Montelongo, Ponciano García-Gutierrez, Gerardo Acosta-García & Guillermo A Silva-Martínez. (2021) Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing. F1000Research 10, pages 358.
Crossref
Crossref
Glenn A. Jacobson, Sharanne Raidal, Morten Hostrup, Luigino Calzetta, Richard Wood-Baker, Mark O. Farber, Clive P. Page & E. Haydn Walters. (2018) Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed. Drug Safety 41:5, pages 441-449.
Crossref
Crossref
James F. Donohue, Nicola A. Hanania, Barry Make, Matthew C. Miles, Donald A. Mahler, Lisa Curry, Robert Tosiello, Alistair Wheeler & Donald P. Tashkin. (2014) One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD. Chest 146:6, pages 1531-1542.
Crossref
Crossref
W J Poppinga, P Muñoz-Llancao, C González-Billault & M Schmidt. (2014) A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases. British Journal of Pharmacology 171:24, pages 5603-5623.
Crossref
Crossref
Casilda Olveira, Ana Muñoz & Adolfo Domenech. (2014) Terapia nebulizada. Año SEPAR. Archivos de Bronconeumología 50:12, pages 535-545.
Crossref
Crossref
Casilda Olveira, Ana Muñoz & Adolfo Domenech. (2014) Nebulized Therapy. SEPAR Year. Archivos de Bronconeumología (English Edition) 50:12, pages 535-545.
Crossref
Crossref
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharma. (2014) Arformoterol: rationale for use in chronic obstructive pulmonary disease. Clinical Investigation 4:5, pages 429-439.
Crossref
Crossref
Donald A. MahlerLaurie A. WatermanJoseph WardAlex H. Gifford. (2014) Comparison of Dry Powder versus Nebulized Beta-Agonist in Patients with COPD Who Have Suboptimal Peak Inspiratory Flow Rate. Journal of Aerosol Medicine and Pulmonary Drug Delivery 27:2, pages 103-109.
Crossref
Crossref
Fulvio Braido, Ilaria Baiardini, Mario Cazzola, Guy Brusselle, Fiorenza Marugo & Giorgio Walter Canonica. (2013) Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD. Respiratory Medicine 107:10, pages 1465-1480.
Crossref
Crossref
Matthew C. Miles, James F. Donohue & Jill A. Ohar. (2012) Nebulized arformoterol: what is its place in the management of COPD?. Therapeutic Advances in Respiratory Disease 7:2, pages 81-86.
Crossref
Crossref
Mike Thomas, Marc Decramer & Denis E O'Donnell. (2013) No room to breathe: the importance of lung hyperinflation in COPD. Primary Care Respiratory Journal 22:1, pages 101-111.
Crossref
Crossref
Teresa A. Schweiger. (2012) Present and Prospective Therapeutic Regimens for COPD. Clinical Medicine Insights: Therapeutics 4, pages CMT.S2106.
Crossref
Crossref
Natya Raghavan, Katherine Webb, Naparat Amornputtisathaporn & Denis E O’Donnell. (2011) Recent advances in pharmacotherapy for dyspnea in COPD. Current Opinion in Pharmacology 11:3, pages 204-210.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:12, pages i-xii.
Crossref
Crossref